NextPharma acquisition of chewable tablet manufacturing site from Takeda complete
.png)
NextPharma has completed their acquisition of a Norway-based manufacturing site, specialising in chewable tablet technologies for calcium/vitamin D3 from pharmaceutical giant Takeda.
European CDMO NextPharma recently announced their acquisition of a state-of-the-art manufacturing facility for chewable tablets in Asker, Norway from Japanese pharmaceutical company Takeda.
In operation for over 50 years, the Asker manufacturing site boasts approximately 170 employees and a portfolio of strengths and flavours for calcium/vitamin D3 chewable tablets and multivitamins. The facility will be included into NextPharma’s existing portfolio of sites and centres of excellence, each of which specialise in different formulations, technologies, and product types. NextPharma hopes that the facility will continue to bolster their unique capabilities and employee expertise with product development and commercial manufacturing businesses to attract new customers. With sites across Europe in Germany, France, Finland, Scotland, and now Norway, NextPharma offers contract services across various healthcare logistics and provides pharmaceutical development, clinical supply, scale-up, and process validation expertise for a range of dosage forms. These forms range from tablets, capsules, granules, gels, softgels, powders, pellets, and more, as well as a wide selection of primary packaging solutions including blister packs, bottles, and tubes.
Bjørn Lie, head of the Asker manufacturing site, commented that “With NextPharma, we are confident that Takeda has chosen a buyer who will help nurture and grow the Asker site. We are all excited about joining the NextPharma team and look forward to working together to drive the long-term development and growth of the business and our people.”
Takeda’s Senior VP, Head of Small Molecules Operating Unit Eduardo Montanha added: “We are pleased to have divested the Asker plant to NextPharma, to whom all of our Asker manufacturing employees have transferred. In NextPharma, we believe we have found the most suitable owner for the site, offering a great fit for the Asker facility and team. We sincerely thank the team in Asker for its work and dedication over the past years and for always putting our customers and patients at the centre of what they do. We with them and NextPharma every success.”
With the acquisition, the CDMO hopes to continue to exceed expectations with high-quality services and delivery to existing customers, and develop and broaden their portfolio of technology for chewable tablets.
CEO of NextPharma Peter Burema stated: “We are excited by the addition of a world-class manufacturing site and a new centre of excellence for chewable tablets to our operational network, allowing us to further broaden our technology offering for both existing and new customers. These technologies, combined with the know-how and expertise of the site’s employees, will continue to benefit patients across the world. On behalf of NextPharma, I welcome our new colleagues, and I am confident that together we will continue to further develop and grow NextPharma as a leading and well-respected European CDMO.”
Source: NextPharma press release Acquisition of manufacturing site in Asker, Norway completed | NextPharma
Stay ahead of the curve at CPHI Barcelona
As companies expand and progress, it can be a challenge keeping up with developments. Join us at CPHI Barcelona and meet the industry movers and shakers who are making things happen. Attendees from disruptive start-ups to established players will keep you in the loop.
Your CPHI Barcelona pass gives you access to all conference sessions, including Formulating the Future, as well as the chance to connect in-person with the global pharma supply chain from 24-26 October, at Fira Barcelona Gran Via. Browse the agenda and secure your pass today!
Related News
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.